Stocks · Healthcare · Biotechnology
Alnylam Pharmaceuticals, Inc. ALNY
$219.89 +0.08% Close, Oct 5, 2026 · NASDAQ · Market cap $29.40B
Strong growthHigh qualityWeak trend
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $4.80B, up 95.1% from a year earlier, accelerating from 82.6% a quarter earlier.
- Operating margin widened to 20.8% from -7.3% a year earlier.
- Over the past year the stock returned -52.3%, behind the S&P 500 by 68.1 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
Growth97Exceptional
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 10%
- Revenue growth, 3-year CAGRTop 13%
- Revenue growth accelerationTop 11%
Quality81Strong
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 4%
- Gross marginTop 30%
- Operating marginTop 12%
- Cash conversion (OCF / net income)Bottom 18%
- Accruals (lower is better)Bottom 11%
- Net debt / EBITDA (lower is better)Top 26%
- Interest coverTop 32%
Value76Positive
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 20%
- Free-cash-flow yieldTop 30%
- EBITDA / enterprise valueTop 27%
- Sales / enterprise valueBottom 43%
Momentum8Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 11%
- 6-month returnBottom 14%
- 1-year return vs S&P 500Bottom 9%
- Distance from 52-week highBottom 21%
- Trend checklist (0–4)Bottom 13%
Revisions54Neutral
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 10%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 47%
- Upside to consensus price targetBottom 49%
Stability60Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 16%
- Maximum drawdown, 3 yearsTop 32%
- Beta vs S&P 500 (lower is better)Top 39%
- Net debt / EBITDA (lower is better)Top 26%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 82.6% | 95.1% | ↑ |
| Gross margin | 83.6% | 79.7% | ↓ |
| Operating margin | -7.3% | 20.8% | ↑ |
| FCF margin | -2.1% | 11.3% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 95.1% | 82.6% | ↑ | Top 10% |
| Gross margin | 79.7% | 83.6% | ↓ | Top 30% |
| Operating margin | 20.8% | -7.3% | ↑ | Top 12% |
| Net margin | 16.8% | -13.0% | ↑ | — |
| Free-cash-flow margin | 11.3% | -2.1% | ↑ | — |
| Return on invested capital | 24.4% | — | Top 4% | |
| Revenue growth, 3-year CAGR | 53.0% | — | Top 13% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.79×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 3.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 7.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -34.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.38×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 3.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.30%
- Shareholder yield
- 0.30%
- Share count change, 1 year
- +6.6%
- Share count change, 3-year CAGR
- +3.5%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +61.5%
- Average 2-day reaction, last 8
- -3.7%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $347.33
- Target vs current price
- +58.0%
- Analysts with a rating
- 52
- Share rating Buy or Strong Buy
- 75%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | -25.8% | -28.3% | -20.2% | -16.6% | — |
| Apr 30, 2026 | +73.2% | +2.8% | +0.6% | +1.3% | -7.6% |
| Feb 12, 2026 | -29.3% | -4.3% | +5.3% | -1.6% | -8.4% |
| Oct 30, 2025 | +228.0% | -6.7% | -9.8% | -7.6% | -26.3% |
| Jul 31, 2025 | +6.2% | +15.4% | +26.0% | +33.7% | +36.6% |
| May 1, 2025 | +50.6% | -3.1% | +5.1% | +11.3% | +23.4% |
| Feb 13, 2025 | -4.8% | -0.4% | -5.6% | -9.1% | -5.6% |
| Oct 31, 2024 | +5.1% | -5.3% | -3.0% | -9.9% | -2.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $1.21 | $1.63 | -25.8% | $1.29B |
| Apr 30, 2026 | $1.51 | $0.87 | +73.2% | $1.17B |
| Feb 12, 2026 | $0.82 | $1.16 | -29.3% | $1.10B |
| Oct 30, 2025 | $1.84 | $0.56 | +228.0% | $1.25B |
| Jul 31, 2025 | -$0.51 | -$0.54 | +6.2% | $773.7M |
| May 1, 2025 | -$0.44 | -$0.89 | +50.6% | $594.2M |
| Feb 13, 2025 | -$0.65 | -$0.62 | -4.8% | $593.2M |
| Oct 31, 2024 | -$0.87 | -$0.92 | +5.1% | $500.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 37.1× | — | — | Top 20% |
| P/E (forward) | 33.0× | — | — | — |
| EV / EBITDA | 25.2× | — | — | Top 27% |
| EV / Sales | 6.03× | — | — | Bottom 43% |
| Free-cash-flow yield | 1.85% | — | — | Top 30% |
| Earnings yield | 2.69% | — | — | Top 20% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.1%
- 200-day average slope (20 days)
- -6.0%
- Distance from 50-day average
- -8.6%
- Distance from 200-day average
- -27.2%
- RSI (14)
- 34.5
- Relative volume
- 0.87×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 82.9%
- Volatility vs own 5-year history
- 95th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.94
- Correlation with S&P 500
- 0.31
- Current drawdown from 1-year high
- -55.2%
- Maximum drawdown, 3 years
- -58.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 20, 2025 | Jul 30, 2026 | -58.2% | 194 days | Not yet recovered |
| Oct 14, 2021 | May 11, 2022 | -42.5% | 144 days | 57 days (Aug 3, 2022) |
| Dec 21, 2022 | Apr 26, 2024 | -40.6% | 337 days | 41 days (Jun 26, 2024) |
| Jan 25, 2021 | May 10, 2021 | -26.8% | 73 days | 28 days (Jun 18, 2021) |
| Oct 16, 2024 | Apr 8, 2025 | -25.4% | 118 days | 36 days (May 30, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $29.40B
- P/E (TTM)
- 37.1
- EPS, diluted (TTM)
- $5.92
- Revenue (TTM)
- $4.80B
- 52-week range
- $197.81 – $495.55
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $844.3M | $1.04B | $1.83B | $2.25B | $3.71B |
| Gross profit | $704.1M | $868.6M | $1.52B | $1.92B | $3.04B |
| Operating income | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| Net income | -$852.8M | -$1.13B | -$440.2M | -$278.2M | $313.7M |
| EPS (diluted) | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.9M | $593.2M | $594.2M | $773.7M | $1.25B | $1.10B | $1.17B | $1.29B |
| Net income | -$111.6M | -$83.8M | -$57.5M | -$66.3M | $251.1M | $186.4M | $206.0M | $164.5M |
| EPS (diluted) | -$0.87 | -$0.65 | -$0.44 | -$0.51 | $1.84 | $1.37 | $1.51 | $1.20 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$641.7M | -$541.3M | $104.2M | -$8.3M | $524.1M |
| Capital expenditure | -$76.4M | -$72.1M | -$62.2M | -$34.3M | -$58.7M |
| Free cash flow | -$718.1M | -$613.3M | $41.9M | -$42.6M | $465.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $246.3M | $259.4M | $147.5M | $303.0M | $250.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $3.31B
- Total assets
- $5.56B
- Total liabilities
- $4.20B
- Total debt
- $1.27B
- Net debt
- -$440.9M
- Shareholders’ equity
- $1.35B
As of Jun 30, 2026 (filed Jul 30, 2026).
Short interest
- Shares sold short
- 7,194,097
- Days to cover
- 4.13
- Change vs previous report
- +13.5%
FINRA short interest, settlement date Sep 15, 2026.